Reply and Banca Generali Bring you the First Reply Sustainable Investment Challenge: make your trades impactful
Following a growing interest in sustainability among the younger generation and the success of last year’s edition, Reply is launching a brand new online Investment Challenge. The international competition, aimed at students and young professionals, is focused on helping participants learn not just how to invest, but how to invest sustainably.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210315005041/en/
For the second consecutive year, the Investment Challenge will be launched in partnership with Banca Generali. Italy’s top private bank has a strong background in sustainable investments and will accompany students through the different levels of the competition.
This year’s edition will also be supported by MainStreet Partners and MIP Politecnico di Milano Graduate School of Business. MainStreet Partners, a London-based company specialising in sustainable investments and portfolio analytics, will provide the ESG ratings for the competition.
MIP Politecnico di Milano Graduate School of Business will also support, having confirmed its commitment to projects with a strong experiential approach and based on advanced experiments in the field of finance and financial investments, such as the Reply Sustainable Investment Challenge.
Participants from all over the world will have virtual capital of $1 million to trade in real-time in the US market. As well as deepening their knowledge of ESG ratings, it will also improve their basic knowledge of finance and investing. The goal of the Challenge is to help participants identify the best companies to invest in, in order to achieve a positive impact for future generations.
Registration will open from 8th March to 16th April. Participants will get the chance to register and learn to invest in a sustainable way in a safe environment through learning pills (bite-sized tutorials), online webinars, and tests on investment and ESG basics.
During the qualification phase – from 19th to 30th April – portfolios will be credited with $1 million and all participants will begin to compete against each other online. They’ll then be ranked and evaluated based on their sustainable investment choices.
The top 100 traders to maximise profits by investing in the best ESG-rated companies, will progress to the final round on 12-14th May and the three most ESG-conscious investors will each receive a prize.
The Investment Challenge is part of Reply’s Challenges programme, which aims to target the most innovative trends in coding creativity, cyber security and finance. Since 2018, more than 100,000 people have joined the Reply Challenges community, and last year more than 8,400 players took part in the first Reply Investment Challenge.
Registration for the Reply Sustainable Investment Challenge is open until 16th April. Sign up at challenges.reply.com.
°°°
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Banca Generali
Banca Generali is a leading private Italian bank. It specialises in financial planning and asset protection for clients, through its network of highly skilled private bankers. The company's strategy is based on four key elements: qualified advice from specialists in protecting family wealth and helping them plan for their future; a cutting-edge product portfolio with solutions tailored to personal needs; innovative wealth management services for looking after tangible and financial assets; and innovative tools that use technology to improve trust between advisor and client. The bank's mission highlights the importance of always having a long-term trusted advisor at the client’s side, to build and take care of their life plan and projects. Listed on the Milan Stock Exchange since November 2006, and 50.1% controlled by the Assicurazioni Generali Group – synonymous with over 180 years of international solidity and security – the bank manages over 74.5 billion euros in assets on behalf of customers (figures as at 31 December 2020). With a widespread presence throughout Italy, it has 45 branches and 137 offices at the disposal of over 2050 financial advisors, and advanced digital contact service operations. In addition, its digital banking platform, www.bancagenerali.it, allows customers to access banking services and operations independently.
MainStreet Partners
MainStreet is the trusted ESG partner of top tier investors, providing a one stop shop for their sustainability requirements at portfolio level. Its clients are some of the most sophisticated and leading Wealth Managers, Asset Managers, Investment Banks, Insurances and Asset Owners in the financial industry. MainStreet Partners is based in London, regulated by the Financial Conduct Authority and consists of two main divisions:
- ESG Advisory – offers solutions for creating ESG multi-asset and multi-manager portfolios with mutual funds, stocks and bonds. The company develops products with its partners which align to the highest standards of sustainability;
- Portfolio Analytics – provides a holistic approach to ESG data analysis such as: transparent and detailed Fund ESG Ratings, assessment of clients’ portfolios to enhance their ESG profile and align them with the “green” regulation.
MIP Politecnico di Milano Graduate School of Business
MIP is the Graduate School of Business of the Politecnico di Milano, one of the best scientific and technological universities in the world, which for more than 40 years has been engaged in providing managerial training programmes for graduates, professionals, companies and institutions.
It has always stood out in the areas of innovation, digital transformation and sustainability. In 2014 it launched Italy’s first Executive MBA in digital learning and today, digital training is an integral part of the entire educational portfolio. This commitment has resulted in MIP moving up in the world's leading rankings, being placed 5th in the QS Online MBA Rankings 2020 and 9th in the FT Online MBA Ranking 2020. The School pays particular attention to issues related to sustainability: it is the only European Business School among B Corp certified establishments, a recognition given to businesses which are characterised by their commitment to sustainable development and to building a more inclusive society. MIP constantly works alongside nationally and internationally renowned companies, building partnerships that make it possible to design training courses aimed at providing the tools needed to meet the challenges of today's markets. Internationalisation is another of MIP’s characteristics: over 70 different nationalities are represented every day in its classrooms and offices.
The training on offer consists of more than 40 Master’s degrees each year, including MBAs and Executive MBAs, a catalogue of over 200 Open programmes dedicated to executive profiles and various customised training courses for companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005041/en/
Contact information
Media:
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +39 02 535761
Aaron Miani
a.miani@reply.com
Tel. +44 (0)20 7730 6000
Banca Generali
Davide Pastore
davide.pastore@bancagenerali.it
Tel. +39 337 1115357
MainStreet Partners
Eleonora Cugini
cugini@mspartners.org
Tel. +44 (0)20 3761 9761
MIP Politecnico di Milano
Graduate School of Business
Marco Gabrieli
mgabrieli@l45.it
Tel. +39 349 5347912
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom